Reduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode Psychosis

Abstract excerpt

Reduced amplitude of mismatch negativity (MMN) is one of the more promising biological markers of schizophrenia. This finding holds true in both early and chronic phases of the disorder, and is compatible with the glutamatergic dysfunction hypothesis. To further establish MMN as a biomarker of aberrant glutamatergic neurotransmission, an exploration for an association with blood levels of glutamatergic amino...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Metabolomics and Mass Spectrometry Studies
• Share to Neuroscience and Neuropharmacology Research
• Share to Schizophrenia research and treatment